ISMRC 2023 Final Programme

15 Tuesday, 2 May 2023 – Scientific Programme SESSION 3 Liquid Biopsy-Based Detection of Primary Cancer & Minimal Residual Cancer – Part I Chairs: Nikolas von Bubnoff, Germany Stefan Schneider, Germany 02:45 – 03:15 p.m. Clinical applications of MRD Nickolas Papadopoulos, USA 03:15 – 03:45 p.m. Liquid biopsy: from discovery to clinical implementation Klaus Pantel, Germany 03:45 – 04:00 p.m. A whole leukocyte-DNA methylome risk score to predict pancreatic cancer Evangelina López De Maturana, Spain 04:00 – 04:15 p.m. A data-driven approach employing au- tomated machine learning reveals novel liquid biopsy methylation biomarkers for breast cancer Ekaterini Alexiou Chatzaki, Greece 04:15 – 06:15 p.m. Poster Sessions IF THE CANCER IS THERE, RaDaR ® WILL HELP YOU FIND IT * *The analytical validation study of the RaDaR assay demonstrates a limit of detection (LoD95%) of 0.001% variant allele fraction (VAF) with 100% specificity RaDaR delivers personalized detection of minimal residual disease (MRD) and recurrence, with a simple blood draw Visit booth 12 for more information Learn more at finditwithRaDaR.com © 2023 NeoGenomics Laboratories, Inc. All rights reserved. RaDaR ® and InVision ® are US, UK, and EU registered trademarks of Inivata Limited, a wholly owned subsidiary of NeoGenomics Laboratories.